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Fascioliasis has been sporadically associated with chronic liver disease on previous stud-
ies. In order to describe the current evidence, we carried out a systematic review to assess
the association between fascioliasis with liver fibrosis, cirrhosis and cancer.
Methodology and Principal Findings
A systematic search of electronic databases (PubMed, LILACS, Scopus, Embase,
Cochrane, and Scielo) was conducted from June to July 2015 and yielded 1,557 published
studies. Among 21 studies that met inclusion and exclusion criteria, 12 studies explored the
association of F. hepatica with liver fibrosis, 4 with liver cirrhosis, and 5 with cancer. Glob-
ally these studies suggested the ability of F. hepatica to promote liver fibrosis and cirrhosis.
The role of F. hepatica in cancer is unknown. Given the heterogeneity of the studies, a
meta-analysis could not be performed.
Conclusions
Future high-quality studies are needed to determine the role of F. hepatica on the develop-
ment of liver fibrosis, liver cirrhosis, and cancer in humans.
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Author Summary
Fascioliasis is a neglected infectious disease caused by the trematode Fasciola. This parasite
(liver fluke) is endemic in many parts of the world including countries from Asia, Africa,
Europe and the Americas. High prevalence rates of fascioliasis has been repeatedly
reported in the Andean region of South America. Liver complications in infected humans
by this fluke have been sporadically reported in the literature. For instance, the relation-
ship between F. hepatica infection and liver fibrosis has been suggested but its association
with cancer is unclear. In this study, we found some evidence of an association between
Fasciola infectionwith liver fibrosis and cirrhosis, but little between Fasciola and cancer.
As Fasciola is highly endemic in some regions of the developing world, our study shed
light on the complications of this parasitic infectionwhich are not that different from
flukes such as Schistosoma or Opisthorchis. We believe that further investigations are
needed in order to elucidate the pathways in how F. hepatica infection causes liver
damage.
Introduction
Food-borne trematodiases are an emerging public health problem in Southeast Asia and Latin
America, and are caused by the following flukes:Clonorchis sinensis, Fasciola gigantica, Fas-
ciola hepatica, Opisthorchis felineus, Opisthorchis viverrini, and Paragonimus spp [1]. Globally,
it has been estimated that approximately 56 million people are infected by these parasites [2].
According to the International Agency for Research on Cancer, two of these parasites (O. viver-
rini and C. sinensis) have been recognized as definitive causes of cancer [3]. However, fasciolia-
sis caused by F. hepatica or F. gigantica has not been clearly associated with cancer to date.
Fascioliasis, as a neglected tropical disease, commonly affects poor people from developing
countries [4]. It has been estimated that at least 2.6 million people are infected with fascioliasis
worldwide [2]. When a combination of serological and parasitological high-sensitive tools are
performed in endemic areas, almost one-third of the population have been reported to be
affected by this liver fluke [5,6]. Even thoughmost patients are asymptomatic, symptoms may
be related to the acute infection (fever and abdominal pain) or to the chronic infection (biliary
colic, cholecystitis and cholangitis) [7]. However, there is a paucity of studies that evaluate the
natural history of subjects infected with fascioliasis (chronic inflammation, liver fibrosis stages,
and carcinogenesis) and in those who were treated (post-infectious liver damage). Therefore,
the long-term of fascioliasis are unknown.
Additionally, several studies reported an association between fascioliasis with other hepatic
complications such as liver fibrosis, cirrhosis, and possibly also with cancer [8]. Due to these
gaps in current knowledge regarding the natural history of fascioliasis, the aim of this study




One of the authors (CM) designed and conducted the electronic search.We searched electronic
databases to identify relevant studies (PubMed, LILACS, Scopus, Embase, Cochrane, and
Scielo) from their inception through July 2015. The electronic search strategy was as follows:
parasite (Fasciola hepatica) AND associated conditions (liver fibrosis, cirrhosis, tumor, cancer,
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neoplasia, malignancy, hepatocellular carcinoma, cholangiocarcinoma) [MeSH] AND associ-
ated terms (oncogene). The search term was adapted to the predominate language of the data-
base. To identify additional candidate studies, we reviewed the reference lists of the eligible
primary studies, narrative reviews, and systematic reviews. The search was conducted in accor-
dance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines [9].
Screening and eligibility criteria
During the screening process, two reviewers working independently (CM, LAM) considered
the potential eligibility of each of the abstracts and titles that resulted from executing the search
strategy. We considered papers available in the following languages: English, Spanish, Italian,
French, German, Turkish, Korean, Chinese, and Japanese. Those eligible publications were
related to a possible direct relationship between fibrosis, cirrhosis, or cancer of the liver and
presence of F. hepatica. During the elegibility process, all eligible studies based on their
abstracts were then reviewed in full text versions. After reviewing the studies in full detail, we
divided them into two groups: group 1, relevant and group 2, irrelevant. Relevant studies were
those related to a possible direct relationship between the exposure and the disease. Irrelevant
publications did not show a direct effect between the exposure and the disease. For example, a
direct effect was when a parasite was found in liver fibrosis or cancer tissue, whereas an indirect
effect (irrelevant) was if the parasite was mimicking a tumor without malignancy cells in the
tissue. Any disagreement was resolved after consensus among all authors.
Exclusion and inclusion criteria
For clinical studies, articles were selected based on the evidence (pathological assessment and/
or images) of Fasciola on fibrosis, cirrhosis or cancer of the liver. For basic research studies,
articles were selected considering any evidence of fascioliasis and genetic alteration events,
either in vivo or in vitro. Those that met the inclusion criteria were included in the final analysis
and discussion (included studies, Fig 1).
Analysis
Our analysis included those publications reporting fibrosis, cirrhosis as well as malignancy and
identification of Fasciola either with direct or not relationship with fibrosis or tumor. Accord-
ingly, any case report of liver fibrosis or malignancy was included in analysis only if a) shows a
direct relationship with fascioliasis, b) occurs as a consequence of previous fascioliasis, or c)
identification of the parasite in the tumor. Any reference meeting one of such criteria, whether
national or international, was recorded, regardless of article type or quality.
Data extraction
Data were then entered in a database covering: title, principal author, year of publication, type
of study, method, results, and any additional comments. Details about the eligible studies are
shown in S1 Table.
Assessment of bias
Quality of studies was not used as a criterion to select or deselect the studies. Given that the pri-
mary outcome of interest was only to assess any relationship between Fasciola and the occur-
rence of liver fibrosis, cirrhosis or cancer; we did not explore the possibility of publication bias.
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Results
Study selection
Our search strategy allowed us to identify 1,557 papers, of which 1,461 were excluded by title,
abstract evaluation, and duplication. Duplicate entries were identified by considering the
author, the year of publication, the title of the article, and the volume, issue and page numbers
of the source. In questionable cases, the abstract texts were compared. As a result, 96 studies
were initially screened by reviewing the corresponding full-text papers. Then, 39 records were
excluded due to lack of consistent evidence related to cancer, fibrosis or cirrhosis. Thus, 57 rec-
ords were then assessed for eligibility according to the criteria outlined previously. Finally, 21
were eligible for our analysis. Type of source included 100% journal manuscripts.
The included studies in the final analysis were divided into three categories based on the tis-
sue effect gathered by F. hepatica exposure. Those three categories of publications were: (i)
those publications related to the presence of F. hepatica and development of fibrosis; (ii) those
publications showing data related to F. hepatica and consequent cirrhosis; (iii) those publica-
tions containing evidence of presence of F. hepatica and diagnosis of any cancer related to liver
or biliary system. Based on such classification, we obtained a total of 1227, 149 and 131 studies
in the first, second and third categories, respectively (Fig 1). As mentioned above, 21 full-text
papers were eligible for final analysis. Five were selected as related to F. hepatica and cancer, 12
were related to F. hepatica and fibrosis, and 4 were related to F. hepatica and cirrhosis.
Information describing the studies analyzed are summarized in S1 Table, including author,
publication year, study design, country, outcome, and evidence.We identified a total of 2 case
reports and 2 case series (19.1%), 8 in vitro studies (.38.1%), and 9 animal assay studies
(42.8%). The publication year ranged from 1974–2015. Geographically, 9 studies were
Fig 1. Flow diagram for selection of studies included in the review.
doi:10.1371/journal.pntd.0004962.g001
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conducted in Europe (42.9%), 9 in the Americas (42.9%), 2 in Asia (9.5%), and 1 in Oceania
(4.8%).
Fascioliasis and liver fibrosis
A total of 12 studies that reported liver fibrosis caused by F. hepatica infection (6 in animals, 4
in vitro studies, one human case series, and one human case report) were selected for this sys-
tematic review. A total of 3234 animals have been reported to have concomitant liver fibrosis
and fascioliasis including bovine, sheep, calves, and pigs [10–21]. The first report of Fasciola
and liver fibrosis was in 1977. Sheep infected with F. hepatica had fibrous tissue surrounding
the hepatic lobules [12]. A higher number of parasites have a direct relationship with the degree
of liver fibrosis in cattle (n = 10) [13]. In 3021 pigs, fascioliasis causes serious hepatic lesions
mainly characterized by severe fibrosis [14]. In addition, periportal fibrosis and collagen depo-
sition around the bile ducts has been also reported in cattle [15,16]. The more chronic injury
around the bile ducts, the greater the periportal fibrosis. In an experimental animal model, the
presence of collagen fibers around the bile ducts and cirrhosis with necrotic foci were found at
7 and 10 weeks post-infectionwith F. hepatica, respectively [17]; but the fibrosis may be revers-
ible after effective anti-parasitic therapy. Whether liver fibrosis is entirely caused by Fascioliasis
or by the host immune response is an open question not yet elucidated.
Among in vitro studies, some identified the gene expression patterns of animals infected
with F. hepatica [18,19]. Up-regulation of fibrosis-related genes in F. hepatica-infected rats
including collagen I, alpha-smooth muscle-actin, platelet-derived growth factor beta receptor,
tissue inhibitor of metalloproteinase II, and activated human stellated cells (HSCs), have been
reported [18]. This suggests that this parasitic infectionmay be associated with the develop-
ment of liver fibrosis by activating the HSCs, similar to other infections (i.e. hepatitis C viral
infection). In infected sheep, microscopic analysis of the livers showed massive infiltration of
inflammatory cells and deposition of collagen at 8-week post-infection [19]. In addition, the
authors reported up-regulation of genes associated with fibrosis (including genes in the JAK--
STAT pathway), tissue repair, remodeling and regeneration (including TNF-α, TGF-β, calpo-
nins, transgelins, osteopontin and adora2b) [19]. Inoculation of native GST of F. hepatica in
goats caused portal fibrosis, inflammatory infiltration with plasma cells, formation of lymphoid
follicles, accumulation of haemosiderin-ladenmacrophages and granulomatous foci [20]. Nat-
ural killer cells have been also found in infected rats around the portal space, centrilobular
veins, periportal fibrosis areas and around collagen [21].
In human studies, one human case with severe fascioliasis was reported to have fibrosis of
portal tracks with fibrosis extending into the parenchyma after a liver biopsy [10]. The other
study included 87 patients with fascioliasis and aimed to characterize by imaging the long-term
liver damage after effective anti-parasitary treatment. This showed that 9 patients continued
having fibrotic liver lesions after 1 year of treatment, but neither cirrhosis nor cancer was docu-
mented on any of these patients during a mean follow-up period of 62 months [11].
Fascioliasis and cirrhosis
Four records were selected that reported cirrhosis as a concomitant condition of fascioliasis,
including 3 in vivo studies and 1 case report. Two additional studies reported sequential pro-
gression from liver fibrosis to cirrhosis in animals infected with F. hepatica [13,17].
Liver cirrhosis has been reported in wild animal models including cows, goats and alpacas
[13,22,24]. Cirrhosis in fascioliasis has been also reported in experimental animal models
[17,23]. The liver damage reported in animals infected -for at least 6 months (chronic infec-
tion)- were described as fibrotic nodules (stage IV of liver fibrosis or cirrhosis) in most of the
Fasciola hepatica Infection and Malignancy
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liver with several degrees of inflammation [22,24]. In 25 goats infected by Fasciola at least for 3
months, the authors reported loss of the lobular pattern, proliferation of bile ducts and fibrosis
in portal areas consistent with cirrhosis after examining both lobes of the liver [22]. In another
study of 40 infected rats, a pool of their bile ducts was collected and it was found that collagen I
and III were significantly increasedwhen compared to controls [23]. This was found similar to
what occurs in cirrhosis.
In humans, one case has been reportedwith cirrhosis [25]. This was a 42-year-old American
woman with fascioliasis who had an ERCP for biliary cirrhosis and cholangiogram suggesting
sclerosing cholangitis [25]. The authors stated that the most direct cause for the primary biliary
cirrhosis and other biliary complications on this patient was likely to be all caused by F. hepatica.
Fascioliasis and cancer
A total of 5 studies were included in our systematic review. Four were in vitro animal studies,
and one was an animal case series.We did not find reports of human cases of cancer explained
by Fasciola.
Chung (2012) investigated the role of TGF-β and IL-4 in the immunosuppression as a hypo-
thetical mechanism of parasite evasion of host immune system [26]. The study demonstrated
that TGF-β and IL-4 are up-regulated as a consequence of F. hepatica infection, TGF-β reaches
its maximum levels of serum at week 2 post infection in each mouse [26]. TGF-β is a potent
known proliferation factor that can also directly inhibit activation of immune system [27].
Both increased proliferation by growth factors and immune evasion are cancer hallmarks [28].
Some studies conducted by Motorna (2011) and Gentile (1998) used the lambda/lacI Big Blue
transgenic mouse model to investigate if genetic damage, as a measure of lacImutations, could
result in liver tissue from infection by F. hepatica [29,30]. There was an increase of lacImuta-
tions in mice with fascioliasis suggesting that the infection increases the risk for complex
hepatic cell mutations rather than mutations stemming frommore definable oxygen radical-
associated events [31,32]. An additional publication reported an indirect relationship between
F. hepatica and cancer by induction of CYP2A5 enzyme (from the parasitic infection) which
participates in the metabolism of carcinogens like B1 (AFB1) and several nitrosamines [32].
The results of this study suggested that F. hepatica can alter the activity of key hepatic enzymes,
which may contribute to accumulation or decrease clearance of carcinogenic compounds
found in food products or environmentally [32]. We found one publication that reported hepa-
tocellular carcinoma (HCC) in cattle with fascioliasis [33].
Our results show a lack of findings/evidenceof fascioliasis and cancer in population-based
studies; quantitative data to measure association with liver disease (Odds Ratio, Relative Risk);
publication bias; quantify significancewith a funnel plot or Egger´s regression asymmetry test;
long-term follow-up of infected cases to asses for further liver damage, and studies in human
and animals.
Discussion
As fascioliasis causes chronic infection in the liver, there is a need to elucidate the long-term
clinical complications of this parasitic infection in humans. This systematic review summarizes
the current evidence that may associate human fascioliasis with liver fibrosis, cirrhosis, and
perhaps cancer.
We showed that Fasciola plays an important role in the development of liver fibrosis, and
cirrhosis in animal models as shown in Fig 2 [10–21,34]. The mechanism of this association
may be due to the activation of HSCs by the cathepsins of the parasite [18]. The intensity of
infectionmay play a role on the development of liver fibrosis during the infection. In addition,
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there is weak evidence in the role of Fasciola in liver fibrosis in humans. This is limited to case
reports. The impact of this association has not been well established in populations highly
prevalent with Fasciola. It will be important to identify at a population level whether patients
with Fasciola are more prompted to develop liver fibrosis and cirrhosis compared to non-
infected patients, after controlling for alcohol consumption and viral etiologies. Furthermore,
the role of early detection, and early treatment of acute or chronic human fascioliasis has not
been studied yet as a strategy to prevent development of fibrosis overtime.
To further justify the plausibility that F. hepatica is associated with fibrosis, there are reports
of fibrosis triggered by related organisms [34,35]. Livers of 35 fallow deer with fascioliasis,
caused by the related parasite Fascioloides magna, were found to contain proliferation of the
epithelium of bile ducts (biliary proliferation, an early stage for biliary cirrhosis) which were
framed with a large quantity of connective tissue [35]. In that study, myofibroblasts especially
HSCs were determined to play an important role in the synthesis of extracellularmatrix com-
ponents in the development of parasitic fibrosis and cirrhosis in the liver of these animals [35].
Similarly, fibrosis has been reported in 15 cows as a consequence of fascioliasis caused by F.
gigantica with presence of proliferative and hyperplasic bile ducts [34].
In carcinogenesis, the evidence of the association of Fasciola infection and cancer is very
limited and no conclusions can be unequivocally reached based on our findings. Fasciola
Fig 2. Schematic representation of liver fibrosis and cirrhosis associated with fascioliasis. (A) Normal architecture of a sheep’s liver.
Haematoxylin and eosin (HE) staining. Taken from Ref. [19]. (B) Juvenile parasite migrating in the peritoneal cavity causing destruction and
haemorrhages in case (HE stain, magnification x100). The biopsy in the peritoneum was performed due to clinical suspicion of metastases Taken from
Ref. [48]. (C) Typical microscopic appearance (400X) of liver from the infected sheep at 8 weeks post infection, massive infiltration of inflammatory cells
and deposition of collagen can be observed. Taken from Ref. [19]. (D) Liver cirrhosis caused by F. hepatica infection. Trichrome stain (100x). Rat.
Authors’ photo gallery. (E) Extensive fibrosis (Fi) with formation of fibrotic nodules (FN), architectural disruption of the liver and regeneration; stage IV or
F4 (cirrhosis). Trichrome stain. Rats. Authors’ photo gallery.
doi:10.1371/journal.pntd.0004962.g002
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infection in animal models has been demonstrated to overexpress a proliferative factor such as
TGF-β, increasemutations (lacI) in mice, and induce CYP2A5 isoenzyme. The later may result
in a reduction on the metabolism of carcinogenic agents. Our results remain informative since
no animal (except for ref.33) or human studies have shown a case of cancer and Fasciola. Fur-
thermore, the evidence of Fasciola-related cancer in animals or humans has not been docu-
mented but the reasons for this are beyond of the aim from this study. We can speculate that as
most endemic areas of fascioliasis are located in resource-poor settings, where the access to
healthcare centers is limited, the chronic consequences from the infection by Fasciola are likely
underreported and therefore, unknown. For instance, there has been a study to suggest an early
presentation of liver cancer in young adults in Peru, but no etiology has been identified [36]. A
recent study on HCC patients in Peru showed that all four K-RAS-mutated HCCs were
unusual I21Mmutants, uncommon K-RASmutations different from codon 12 mutations have
been associated with cholangiocarcinoma produced by viral infections or fluke infestations
[37,38]. To the best of our knowledge, there has not been any association between liver cancer
in Peru and fascioliasis to date. F. hepatica is able to induce DNA damage through action of
mutational mediators such as reactive nitric species and reactive oxygen species [39]. Both cir-
rhosis and genomic instability combined to a protumorigenic environment caused by CYP2A5
mutated contribute to cell transformation.
The results from this systematic review are interesting for several reasons. Most of the peo-
ple chronically infected by Fasciola are asymptomatic but they are not necessarily free of
inflammation [7]. There is a degree of inflammation into the liver in those chronically infected
individuals by means of an increase in serum lipid peroxidation and a decrease in antioxidant
enzymes, but the period between initial infection and developing of liver fibrosis in humans is
still unknown [40]. Intensity of infection, length of infection, re-infections, other liver diseases,
alcohol consumption, co-infectionwith chronic viral hepatitis, among others; are factors to be
considered when assessing liver disease in infected individuals by Fasciola in endemic areas.
For example, alcohol consumption can exacerbate cholangiofibrosis in hamsters infected by
Opisthorchis, another liver fluke infecting bile ducts, but no studies in Fasciola have been per-
formed [41]. One also might think that the inflammation from the infectionwould resolve
after effective antiparasitic therapy but this has not yet been assessed. Future longitudinal stud-
ies in human from endemic areas may investigate further our findings. In addition, future stud-
ies may face the challenges of Fasciola resistant to triclabendazole, the only drug available for
Fasciola nowadays [42].
The major limitation of our study is the absence of previously published population studies
that assessed the role of F. hepatica in liver fibrosis, cirrhosis, and cancer. Therefore, our results
come from basic science studies, animal models, case reports, and case series. However, no
studies have previously systematically reviewed the literature in this important topic, and our
study serves to suggest an association between F. hepatica with liver fibrosis and cirrhosis.
Other limitations include publication bias, and lack of longitudinal follow-up of infected
patients. Despite these limitations, we believe that our study makes an important contribution
to recognize several potential severe chronic complications associated with human fascioliasis,
and will be the base of future population studies that assess these associations. The results of
our study and future studies will be of use for vulnerable populations affected by this fluke, in
areas like the Peruvian Highlands, to prevent the complications caused by fascioliasis. Further-
more, it is relevant to investigate the existence of an inter-relationships between F. hepatica
and gastrointestinal tract microbes that may affect the progression of fascioliasis. For instance,
Helicobacter pylori infection has been closely associated withO. viverrini-associated cholangio-
carcinoma suggesting that the liver fluke is a reservoir of the carcinogenic bacterium and thus
making plausible that the co-infectionmay promote the pathogenesis of cholangiocarcinoma
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[43,44]. Additionally, studies of the biliarymicrobiota should reveal the role of host microbial
content in the development of fascioliasis and whether alterations or changes in microbiota
occur as a consequence of the liver damage. Most recently, compositional shifts in the tissue
microbiome of O. viverrini-associated cholangiocarcinomawere identified suggesting that
changes in the microenvironment occurred after parasite infection can trigger tumorigenesis
[45].
Also, comparison of similarities and dissimilarities with the pathophysiological processes
leading to liver cancer and cholangiocarcinoma, induced by infectionwithO. viverrini and C.
sinensis, and including well-characterized liver fluke derivedmetabolites likely will advance
this task [46,47]. We conclude that there is some evidence of an association between Fasciola
infectionwith liver fibrosis and cirrhosis but no strong evidence between Fasciola and cancer.
There is a need of long-term population studies to assess the association of F. hepatica with
liver fibrosis, cirrhosis and cancer in endemic populations.
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